1. Scrip
  2. >>Business
  3. >>Strategy

CEO Interview: Ulcerative Colitis Trial Shows Abivax's HIV Candidate Has Broader Potential

 
• By Sten Stovall

Abivax Phase IIa data for its lead asset showed impressive results in ulcerative colitis. The biotech's CEO tells Scrip trials in Crohn's disease and rheumatoid arthritis will now follow.

Gastrointestinal tract
Abivax Says Good Phase II Data In UC Transforms Pipeline Prospects • Source: Shutterstock

Abivax will start trialing its novel lead compound in other anti-inflammation conditions after a Phase IIa trial showed ABX464 to be safe and effective in ulcerative colitis patients who are refractive to current therapies, including anti-TNF treatment, the French biotech's CEO told Scrip.

Orally administered ABX464 had already shown good results in a recently completed Phase II clinical trial to demonstrate it can deplete HIV reservoirs with a lasting effect of up to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

More from Business

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.